Molecular pathology of cyclooxygenase-2 in neoplasia

Cyclooxygenase (COX)-2 levels are elevated in several types of human cancer tissues. Nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit both the COX-1 and COX-2 protein, the two enzymes that convert arachidonic acids to prostaglandins. Regular use of such NSAIDs significantly reduces the risk and spread of some cancers. The objective of this study was to elucidate the molecular pathology of neoplasms that overexpress COX-2. Epidemiological data and clinical studies were analyzed and compared with results of studies of human tumor tissues, animal models, and cultured tumor cells. COX-2, but not COX-1, is highly expressed in human colon carcinoma, squamous cell carcinoma of the esophagus, and skin cancer. COX-2 is inducible by oncogenes ras and scr, interleukin-1, hypoxia, benzo[a]pyrene, ultraviolet light, epidermal growth factor, transforming growth factor beta, and tumor necrosis factor alpha. Dexamethasone, antioxidants, and tumor-suppressor protein p53 suppress COX-2 expression. COX-2 synthesizes prostaglandin E2 (PGE2) which stimulates bcl-2 and inhibits apoptosis, and induces interleukin-6 (IL-6) which enhances haptoglobin synthesis. PGE2 is associated with tumor metastases, IL-6 with cancer cell invasion, and haptoglobin with implantation and angiogenesis. Drastic reduction in polyp number results from COX-2 gene knockout as well as from selective COX-2 inhibition in a mouse model of human familial adenomatous polyposis. Nonselective NSAIDs, for instance aspirin, and selective COX-2 inhibitors such as celecoxib (SC-58635) and NS-398 suppress azoxymethane-induced colon carcinogenesis in rats. Aspirin, indomethacin, and ibuprofen decrease cultured lung cancer cell proliferation. Selective inhibition of COX-2 is preferable to nonselective inhibition. It reduces cancer cell proliferation, induces cancer cell apoptosis, and spares COX-1-induced cytoprotection of the gastrointestinal tract.

This article has been cited by other articles:

				N. Wakimoto, I. Wolf, D. Yin, J. O'Kelly, T. Akagi, L. Abramovitz, K. L. Black, H.-H. Tai, and H. P. Koeffler Nonsteroidal Anti-inflammatory Drugs Suppress Glioma via 15-Hydroxyprostaglandin Dehydrogenase Cancer Res., September 1, 2008; 68(17): 6978 - 6986. [Abstract] [Full Text] [PDF]

				E. Fosslien Cancer Morphogenesis: Role of Mitochondrial Failure Ann. Clin. Lab. Sci., January 1, 2008; 38(4): 307 - 330. [Abstract] [Full Text] [PDF]

				C. Bergmann, L. Strauss, R. Zeidler, S. Lang, and T. L. Whiteside Expansion of Human T Regulatory Type 1 Cells in the Microenvironment of Cyclooxygenase 2 Overexpressing Head and Neck Squamous Cell Carcinoma Cancer Res., September 15, 2007; 67(18): 8865 - 8873. [Abstract] [Full Text] [PDF]

				S. Signoroni, M. Frattini, T. Negri, E. Pastore, E. Tamborini, P. Casieri, M. Orsenigo, L. Da Riva, P. Radice, P. Sala, et al. Cyclooxygenase-2 and Platelet-Derived Growth Factor Receptors as Potential Targets in Treating Aggressive Fibromatosis Clin. Cancer Res., September 1, 2007; 13(17): 5034 - 5040. [Abstract] [Full Text] [PDF]

				R. Benoliel, J. Epstein, E. Eliav, R. Jurevic, and S. Elad Orofacial Pain in Cancer: Part I--Mechanisms J. Dent. Res., June 1, 2007; 86(6): 491 - 505. [Abstract] [Full Text] [PDF]

				R. Benoliel, J. Epstein, E. Eliav, R. Jurevic, and S. Elad Orofacial Pain in Cancer: Part I--Mechanisms Journal of Dental Research, June 1, 2007; 86(6): 491 - 505. [Abstract] [Full Text] [PDF]

				K. E. Eblin, T. G. Bredfeldt, S. Buffington, and A. J. Gandolfi Mitogenic Signal Transduction Caused by Monomethylarsonous Acid in Human Bladder Cells: Role in Arsenic-Induced Carcinogenesis Toxicol. Sci., February 1, 2007; 95(2): 321 - 330. [Abstract] [Full Text] [PDF]

				D. Schottenfeld and J. Beebe-Dimmer Alleviating the Burden of Cancer: A Perspective on Advances, Challenges, and Future Directions. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2049 - 2055. [Abstract] [Full Text] [PDF]

				W. H. Faour, Q. He, A. Mancini, D. Jovanovic, J. Antoniou, and J. A. Di Battista Prostaglandin E2 Stimulates p53 Transactivational Activity through Specific Serine 15 Phosphorylation in Human Synovial Fibroblasts: ROLE IN SUPPRESSION OF c/EBP/NF-{kappa}B-MEDIATED MEKK1-INDUCED MMP-1 EXPRESSION J. Biol. Chem., July 21, 2006; 281(29): 19849 - 19860. [Abstract] [Full Text] [PDF]

				S. Grosch, T. J. Maier, S. Schiffmann, and G. Geisslinger Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst, June 7, 2006; 98(11): 736 - 747. [Abstract] [Full Text] [PDF]

				G. Cohen, R. Mustafi, A. Chumsangsri, N. Little, J. Nathanson, S. Cerda, S. Jagadeeswaran, U. Dougherty, L. Joseph, J. Hart, et al. Epidermal Growth Factor Receptor Signaling Is Up-regulated in Human Colonic Aberrant Crypt Foci Cancer Res., June 1, 2006; 66(11): 5656 - 5664. [Abstract] [Full Text] [PDF]

				H. Zhi, L. Wang, J. Zhang, C. Zhou, F. Ding, A. Luo, M. Wu, Q. Zhan, and Z. Liu Significance of COX-2 expression in human esophageal squamous cell carcinoma Carcinogenesis, June 1, 2006; 27(6): 1214 - 1221. [Abstract] [Full Text] [PDF]

				J. Vanamala, T. Leonardi, B. S. Patil, S. S. Taddeo, M. E. Murphy, L. M. Pike, R. S. Chapkin, J. R. Lupton, and N. D. Turner Suppression of colon carcinogenesis by bioactive compounds in grapefruit Carcinogenesis, June 1, 2006; 27(6): 1257 - 1265. [Abstract] [Full Text] [PDF]

				M. Bernstein, H. Kovar, M. Paulussen, R. L. Randall, A. Schuck, L. A. Teot, and H. Juergensg Ewing's Sarcoma Family of Tumors: Current Management. Oncologist, May 1, 2006; 11(5): 503 - 519. [Abstract] [Full Text] [PDF]

				R. S. Pruthi, J. E. Derksen, D. Moore, C. C. Carson, G. Grigson, C. Watkins, and E. Wallen Phase II Trial of Celecoxib in Prostate-Specific Antigen Recurrent Prostate Cancer after Definitive Radiation Therapy or Radical Prostatectomy. Clin. Cancer Res., April 1, 2006; 12(7): 2172 - 2177. [Abstract] [Full Text] [PDF]

				N. F. Lamour and C. E. Chalfant Ceramide-1-phosphate: The "missing" link in eicosanoid biosynthesis and inflammation Mol. Interv., December 1, 2005; 5(6): 358 - 367. [Abstract] [Full Text] [PDF]

				E. Fosslien Cardiovascular Complications of Non-Steroidal Anti-Inflammatory Drugs Ann. Clin. Lab. Sci., October 1, 2005; 35(4): 347 - 385. [Abstract] [Full Text] [PDF]

				H M. Prince, L. Mileshkin, A. Roberts, V. Ganju, C. Underhill, J. Catalano, R. Bell, J. F. Seymour, D. Westerman, P. J. Simmons, et al. A Multicenter Phase II Trial of Thalidomide and Celecoxib for Patients with Relapsed and Refractory Multiple Myeloma Clin. Cancer Res., August 1, 2005; 11(15): 5504 - 5514. [Abstract] [Full Text] [PDF]

				M. E. Winters, A. I. Mehta, E. F. Petricoin III, E. C. Kohn, and L. A. Liotta Supra-additive Growth Inhibition by a Celecoxib Analogue and Carboxyamido-triazole Is Primarily Mediated through Apoptosis Cancer Res., May 1, 2005; 65(9): 3853 - 3860. [Abstract] [Full Text] [PDF]

				D. A. Heller, C. A. Clifford, M. H. Goldschmidt, D. E. Holt, M. J. Manfredi, and K. U. Sorenmo Assessment of Cyclooxygenase-2 Expression in Canine Hemangiosarcoma, Histiocytic Sarcoma, and Mast Cell Tumor Vet. Pathol., May 1, 2005; 42(3): 350 - 353. [Abstract] [Full Text] [PDF]

				R. E. Brown Morphoproteomic Analysis of Osteolytic Langerhans Cell Histiocytosis with Therapeutic Implications Ann. Clin. Lab. Sci., April 1, 2005; 35(2): 131 - 136. [Abstract] [Full Text] [PDF]

				H. H.-X. Xia, S. T. Zhang, S. K. Lam, M. C.-M. Lin, H. F. Kung, and B. C.-Y. Wong Expression of macrophage migration inhibitory factor in esophageal squamous cell carcinoma and effects of bile acids and NSAIDs Carcinogenesis, January 1, 2005; 26(1): 11 - 15. [Abstract] [Full Text] [PDF]

				D. S. Dandekar and B. L. Lokeshwar Inhibition of Cyclooxygenase (COX)-2 Expression by Tet-Inducible COX-2 Antisense cDNA in Hormone-Refractory Prostate Cancer Significantly Slows Tumor Growth and Improves Efficacy of Chemotherapeutic Drugs Clin. Cancer Res., December 1, 2004; 10(23): 8037 - 8047. [Abstract] [Full Text] [PDF]

				C. Han, A. J. Demetris, Y. Liu, J. H. Shelhamer, and T. Wu Transforming Growth Factor-{beta} (TGF-{beta}) Activates Cytosolic Phospholipase A2{alpha} (cPLA2{alpha})-mediated Prostaglandin E2 (PGE)2/EP1 and Peroxisome Proliferator-activated Receptor-{gamma} (PPAR-{gamma})/Smad Signaling Pathways in Human Liver Cancer Cells: A NOVEL MECHANISM FOR SUBVERSION OF TGF-{beta}-INDUCED MITOINHIBITION J. Biol. Chem., October 22, 2004; 279(43): 44344 - 44354. [Abstract] [Full Text] [PDF]

				T. A. Wilgus, V. K. Bergdall, K. L. Tober, K. J. Hill, S. Mitra, N. A. Flavahan, and T. M. Oberyszyn The Impact of Cyclooxygenase-2 Mediated Inflammation on Scarless Fetal Wound Healing Am. J. Pathol., September 1, 2004; 165(3): 753 - 761. [Abstract] [Full Text] [PDF]

				M. A. Kern, M. M. Schoneweiss, D. Sahi, M. Bahlo, A. M. Haugg, H. U. Kasper, H. P. Dienes, H. Kaferstein, K. Breuhahn, and P. Schirmacher Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice Carcinogenesis, July 1, 2004; 25(7): 1193 - 1199. [Abstract] [Full Text] [PDF]

				K. J. Trouba and D. R. Germolec Micromolar Concentrations of Sodium Arsenite Induce Cyclooxygenase-2 Expression and Stimulate p42/44 Mitogen-Activated Protein Kinase Phosphorylation in Normal Human Epidermal Keratinocytes Toxicol. Sci., June 1, 2004; 79(2): 248 - 257. [Abstract] [Full Text] [PDF]

				P. Nix, M. Lind, J. Greenman, N. Stafford, and L. Cawkwell Expression of Cox-2 protein in radioresistant laryngeal cancer Ann. Onc., May 1, 2004; 15(5): 797 - 801. [Abstract] [Full Text] [PDF]

				C. Han, J. Leng, A. J. Demetris, and T. Wu Cyclooxygenase-2 Promotes Human Cholangiocarcinoma Growth: Evidence for Cyclooxygenase-2-Independent Mechanism in Celecoxib-Mediated Induction of p21waf1/cip1 and p27kip1 and Cell Cycle Arrest Cancer Res., February 15, 2004; 64(4): 1369 - 1376. [Abstract] [Full Text] [PDF]

				E. Fosslien Mitochondrial Medicine - Cardiomyopathy Caused by Defective Oxidative Phosphorylation Ann. Clin. Lab. Sci., October 1, 2003; 33(4): 371 - 395. [Abstract] [Full Text] [PDF]

				C. A. DiPerna, R. D. Bart, E. M. Sievers, Y. Ma, V. A. Starnes, and R. M. Bremner Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma J. Thorac. Cardiovasc. Surg., October 1, 2003; 126(4): 1129 - 1133. [Abstract] [Full Text] [PDF]

				S. Tsutsumi, S. Mima, W. Tomisato, T. Hoshino, T. Tsuchiya, and T. Mizushima Molecular Mechanism of Adaptive Cytoprotection Induced by Ethanol in Human Gastric Cells Experimental Biology and Medicine, October 1, 2003; 228(9): 1089 - 1095. [Abstract] [Full Text] [PDF]

				E. F.J. de Vries, A. van Waarde, A. R. Buursma, and W. Vaalburg Synthesis and In Vivo Evaluation of 18F-Desbromo-DuP-697 as a PET Tracer for Cyclooxygenase-2 Expression J. Nucl. Med., October 1, 2003; 44(10): 1700 - 1706. [Abstract] [Full Text] [PDF]

				D. Bagga, L. Wang, R. Farias-Eisner, J. A. Glaspy, and S. T. Reddy Differential effects of prostaglandin derived from omega -6 and omega -3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion PNAS, February 18, 2003; 100(4): 1751 - 1756. [Abstract] [Full Text] [PDF]

				P. Greenwald Cancer Prevention Clinical Trials J. Clin. Oncol., September 15, 2002; 20(90001): 14s - 22. [Abstract] [Full Text] [PDF]

				S. Battersby, S. C. Boddy, H. O. D. Critchley, and H. N. Jabbour Expression and Localization of Endothelial Monocyte-Activating Polypeptide II in the Human Endometrium across the Menstrual Cycle: Regulation of Expression by Prostaglandin E2 J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3928 - 3935. [Abstract] [Full Text] [PDF]

				A. Murakami, D. Takahashi, T. Kinoshita, K. Koshimizu, H. W. Kim, A. Yoshihiro, Y. Nakamura, S. Jiwajinda, J. Terao, and H. Ohigashi Zerumbone, a Southeast Asian ginger sesquiterpene, markedly suppresses free radical generation, proinflammatory protein production, and cancer cell proliferation accompanied by apoptosis: the {alpha},{beta}-unsaturated carbonyl group is a prerequisite Carcinogenesis, May 1, 2002; 23(5): 795 - 802. [Abstract] [Full Text] [PDF]

				J. M. Wallace Nutritional and Botanical Modulation of the Inflammatory Cascade--Eicosanoids, Cyclooxygenases, and Lipoxygenases-- As an Adjunct in Cancer Therapy Integr Cancer Ther, March 1, 2002; 1(1): 7 - 37. [Abstract] [PDF]

				K. M. Leahy, R. L. Ornberg, Y. Wang, B. S. Zweifel, A. T. Koki, and J. L. Masferrer Cyclooxygenase-2 Inhibition by Celecoxib Reduces Proliferation and Induces Apoptosis in Angiogenic Endothelial Cells in Vivo Cancer Res., February 1, 2002; 62(3): 625 - 631. [Abstract] [Full Text] [PDF]

				R. E. Brown HER-2/neu-Positive Breast Carcinoma: Molecular Concomitants by Proteomic Analysis and their Therapeutic Implications Ann. Clin. Lab. Sci., January 1, 2002; 32(1): 12 - 21. [Abstract] [Full Text] [PDF]

				S. I. Mohammed, P. F. Bennett, B. A. Craig, N. W. Glickman, A. J. Mutsaers, P. W. Snyder, W. R. Widmer, A. E. DeGortari, P. L. Bonney, and D. W. Knapp Effects of the Cyclooxygenase Inhibitor, Piroxicam, on Tumor Response, Apoptosis, and Angiogenesis in a Canine Model of Human Invasive Urinary Bladder Cancer Cancer Res., January 1, 2002; 62(2): 356 - 358. [Abstract] [Full Text] [PDF]

				Z. A. Massy and S. K. Swan Cyclooxygenase-2 and atherosclerosis: friend or foe? Nephrol. Dial. Transplant., December 1, 2001; 16(12): 2286 - 2289. [Full Text] [PDF]

				S. Zha, W. R. Gage, J. Sauvageot, E. A. Saria, M. J. Putzi, C. M. Ewing, D. A. Faith, W. G. Nelson, A. M. De Marzo, and W. B. Isaacs Cyclooxygenase-2 Is Up-Regulated in Proliferative Inflammatory Atrophy of the Prostate, but not in Prostate Carcinoma Cancer Res., December 1, 2001; 61(24): 8617 - 8623. [Abstract] [Full Text] [PDF]

				B. L. Upham and J. G. Wagner Toxicant-Induced Oxidative Stress in Cancer Toxicol. Sci., November 1, 2001; 64(1): 1 - 3. [Abstract] [Full Text] [PDF]

				E. Fosslien Molecular Pathology of Cyclooxygenase-2 in Cancer-induced Angiogenesis Ann. Clin. Lab. Sci., October 1, 2001; 31(4): 325 - 348. [Abstract] [Full Text] [PDF]

				C. Martinez, E. Garcia-Martin, J. M. Ladero, J. Sastre, F. Garcia-Gamito, M. Diaz-Rubio, and J. A. G. Agundez Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk Carcinogenesis, August 1, 2001; 22(8): 1323 - 1326. [Abstract] [Full Text] [PDF]

				E. M. P. de Almeida, C. Piche, J. Sirois, and M. Dore Expression of Cyclo-oxygenase-2 in Naturally Occurring Squamous Cell Carcinomas in Dogs J. Histochem. Cytochem., July 1, 2001; 49(7): 867 - 876. [Abstract] [Full Text] [PDF]

				Abstracts of Presentations at the Annual Meeting of the Association of Clinical Scientists in Chapel Hill, NC, on 9 to 12 May 2001 Ann. Clin. Lab. Sci., July 1, 2001; 31(3): 297 - 318. [Full Text] [PDF]

				R. C. Harris and M. D. Breyer Physiological regulation of cyclooxygenase-2 in the kidney Am J Physiol Renal Physiol, July 1, 2001; 281(1): F1 - F11. [Abstract] [Full Text] [PDF]

				T. Lahiri, J. D. Laporte, P. E. Moore, R. A. Panettieri Jr., and S. A. Shore Interleukin-6 family cytokines: signaling and effects in human airway smooth muscle cells Am J Physiol Lung Cell Mol Physiol, June 1, 2001; 280(6): L1225 - L1232. [Abstract] [Full Text] [PDF]

				M. Oshima, N. Murai, S. Kargman, M. Arguello, P. Luk, E. Kwong, M. M. Taketo, and J. F. Evans Chemoprevention of Intestinal Polyposis in the Apc{{Delta}}716 Mouse by Rofecoxib, a Specific Cyclooxygenase-2 Inhibitor Cancer Res., February 1, 2001; 61(4): 1733 - 1740. [Abstract] [Full Text]

				E. Fosslien Mitochondrial Medicine - Molecular Pathology of Defective Oxidative Phosphorylation Ann. Clin. Lab. Sci., January 1, 2001; 31(1): 25 - 67. [Abstract] [Full Text] [PDF]

				R. C. HARRIS Cyclooxygenase-2 in the Kidney J. Am. Soc. Nephrol., December 1, 2000; 11(12): 2387 - 2394. [Full Text]

				A. Murakami, Y. Nakamura, T. Tanaka, K. Kawabata, D. Takahashi, K. Koshimizu, and H. Ohigashi Suppression by citrus auraptene of phorbol ester- and endotoxin-induced inflammatory responses: role of attenuation of leukocyte activation Carcinogenesis, October 1, 2000; 21(10): 1843 - 1850. [Abstract] [Full Text] [PDF]